Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis - PubMed
10 hours ago
- #network meta-analysis
- #oral drugs
- #multiple sclerosis
- Systematic review and network meta-analysis evaluated efficacy and safety of oral disease-modifying drugs for relapsing-remitting multiple sclerosis (RRMS).
- Included 15 randomized controlled trials with 14,869 participants, analyzing drugs like Siponimod, Ponesimod, Laquinimod, Fingolimod, Cladribine, and Dimethyl Fumarate.
- Siponimod (2 mg) ranked highest in reducing annualized relapse rates (SUCRA = 86.9%), while Laquinimod (0.3 mg) ranked lowest (SUCRA = 10.1%).
- For adverse events leading to discontinuation, Fingolimod (0.25 mg) was safest (SUCRA = 83.1%), and Siponimod (10 mg) was least favorable (SUCRA = 3.1%).
- Findings suggest Siponimod (2mg) is most effective, and Fingolimod (0.25 mg) shows safety advantages, but further validation is needed for clinical application.